Optimum Timing for Surgery After Pre-operative Radiotherapy 6 vs 12 Weeks

NCT ID: NCT01037049

Last Updated: 2018-09-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

237 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-10-16

Study Completion Date

2019-12-08

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to determine whether greater rectal cancer downstaging and regression occurs when surgery is delayed to 12 weeks after completion of radiotherapy/chemotherapy compared to 6 weeks.

Hypothesis: Greater downstaging and tumour regression is observed when surgery is delayed to 12 weeks after completion of CRT compared to 6 weeks.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Adenocarcinoma of the Rectum Adenocarcinoma Adenocarcinoma, Mucinous Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Neoplasms, Cystic, Mucinous, and Serous Colorectal Neoplasms Intestinal Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site Digestive System Diseases Gastrointestinal Diseases Intestinal Diseases Rectal Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group 1

Patients who have surgery at 6 weeks after radiotherapy/chemoradiotherapy

Group Type NO_INTERVENTION

No interventions assigned to this group

Group 2

Patients who have surgery at 12 weeks after radiotherapy/chemoradiotherapy

Group Type EXPERIMENTAL

Patients who have surgery at 12 weeks after radiotherapy/chemoradiotherapy

Intervention Type OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Patients who have surgery at 12 weeks after radiotherapy/chemoradiotherapy

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Aged \> 18
* Informed written consent
* Histological confirmation of adenocarcinoma of rectum
* Undergoing pre-operative radiotherapy/ chemotherapy
* Completion of pre-operative treatment

Exclusion Criteria

* Aged \< 18
* Absence of pre-operative RT/CT
* Medical/ psychiatric conditions that compromise the patients ability to give informed consent
* Contra-indications to MRI, i.e. hip prothesis, cardiac pacemaker
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Royal Marsden NHS Foundation Trust

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Diana Tait

Role: PRINCIPAL_INVESTIGATOR

Royal Marsden NHS Foundation Trust

Gina Brown

Role: PRINCIPAL_INVESTIGATOR

Royal Marsden Hospitals NHS Foundation Trust

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hospital Alemão Oswaldo Cruz

São Paulo, , Brazil

Site Status

Jewish General Hospital

Montreal, Quebec, Canada

Site Status

Bank of Cyprus Oncology Centre

Nicosia, , Cyprus

Site Status

Hinchingbrooke Hospital

Huntingdon, Cambridgeshire, United Kingdom

Site Status

County Durham and Darlington NHS Trust (University Hospital of North Durham)

Durham, County Durham, United Kingdom

Site Status

North Tees and Hartlepool NHS Trust (University Hospital of North Tees)

Stockton-on-Tees, County Durham, United Kingdom

Site Status

Dorset County Hospital NHS Foundation Trust

Dorchester, Dorset, United Kingdom

Site Status

Poole Hospital NHS Foundation Trust

Poole, Dorset, United Kingdom

Site Status

Essex County Hospital

Colchester, Essex, United Kingdom

Site Status

Portsmouth Hospitals NHS Trust (Queen Alexandra Hospital)

Portsmouth, Hampshire, United Kingdom

Site Status

Medway NHS Foundation Trust

Gillingham, Kent, United Kingdom

Site Status

North West London Hospitals NHS Trust (Northwick Park Hospital)

Harrow, Middlesex, United Kingdom

Site Status

James Paget University Hospitals NHS Foundation Trust

Great Yarmouth, Norfolk, United Kingdom

Site Status

Epsom and St Helier's Hospitals NHS Trust

Carshalton, Surrey, United Kingdom

Site Status

St Richard's Hospital

Chichester, West Sussex, United Kingdom

Site Status

Mid Yorkshire Hospitals NHS Trust (Pinderfields Hospital)

Wakefield, West Yorkshire, United Kingdom

Site Status

Royal United Hospital NHS Trust

Bath, , United Kingdom

Site Status

Sandwell and West Birmingham Hospitals NHS Trust

Birmingham, , United Kingdom

Site Status

Croydon University Hospital

Croydon, , United Kingdom

Site Status

St Bartholomew's Hospital

London, , United Kingdom

Site Status

St George's Healthcare NHS Trust

London, , United Kingdom

Site Status

Pennine Acute Hospitals NHS Trust

Manchester, , United Kingdom

Site Status

Royal Marsden NHS Trust

Sutton, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Brazil Canada Cyprus United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CCR3227

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.